The Schedule

7:30 Registration opens, breakfast available

8:00-8:50 Breakfast and networking

8:50 Welcome and introduction of Keynote 1

    Ryan Wilcox, MD, PhD, Michigan Medicine, Division of Hematology Oncology

9:00-10:00 Keynote: How the molecular biology of multiple myeloma informs current and future therapy - Senator Vandenberg Room

 Jonathan Licht, MD

 President and Chief Scientific Officer, Van Andel Institute, Grand Rapids, Michigan

10:00-10:15 Break

10:15-11:30 Two concurrent sessions

Session A (T-Cell Lymphomas) - Senator Vandenberg Room A

10:15-10:40   When CHOP doesn’t cut it: Rare T-cell lymphomas - Panel Discussion

Shannon Carty, MD, Michigan Medicine, Division of Hematology Oncology

Jonathan Weiss, MD, Michigan Medicine, Division of Hematology Oncology

Ryan Wilcox, MD, PhD, Michigan Medicine, Division of Hematology Oncology

10:40-11:05          PTCL, NOS classification and treatment  - Panel Discussion

Carlos Murga-Zamalioa, MD, University of Chicago-Illinois, Pathology

Ryan Wilcox, MD, PhD, Michigan Medicine, Division of Hematology Oncology

11:05-11:30   T-ALL update: Classification & treatment 

Patrick Burke, MD, Michigan Medicine, Division of Hematology Oncology

Session B (Myeloma) - Senator Vandenberg Room B

10:15-10:40   Immunotherapy for myeloma debate : CAR-T or T-cell redirection therapy? - Panel Discussion

Matthew Pianko, MD, Michigan Medicine, Division of Hematology Oncology

Marcus Geer, MD, Michigan Medicine, Division of Hematology Oncology (Tentative)

10:40-11:05            Updates in light chain AL amyloidosis (tentative title)

Jeffrey Zonder, MD, Karmanos Cancer Institute, Wayne State University

11:05-11:30     Case-based discussion : challenges in relapsed/refractory myeloma - Panel Discussion

Matthew Pianko, MD, Michigan Medicine, Division of Hematology Oncology

Jeffrey Zonder, MD, Karmanos Cancer Institute, Wayne State University

Erica Campagnaro, MD, Michigan Medicine, Division of Hematology Oncology

11:30-1:00 Lunch - North Concourse

 Optional Product Theaters - Pearl Room, Emerald Rooms A and B

1:00-2:00 Keynote Address - Menin inhibitors as a treatment for AML: from discovery to FDA approval and beyond - Senator Vandenberg Room

Jolanta Grembecka, PhD

Professor, Michigan Medicine, Pathology

2:00-2:15 Break

2:15-3:30 Two concurrent disease-specific sessions

Session A (B-cell Lymphomas) - Senator Vandenberg Room A

2:15-3:30         Lymphoma lightning rounds: Case-based discussions and debates. Is there a role for ctDNA and MRD   assessments in aggressive lymphomas? Updates: Bispecific antibodies and “chemo free” regimens.   Optimal frontline and second-line regimens in indolent lymphomas  - Panel Discussion

Yasmin Karimi, MD, Michigan Medicine, Division of Hematology Oncology

Jonathan Weiss, MD, Michigan Medicine, Division of Hematology Oncology

and others

Session B (Myeloid leukemias) - Senator Vandenberg Room B

2:15-2:45         The clinical experience with menin inhibitors 

Patrick Burke, MD, Michigan Medicine, Division of Hematology Oncology

2:45-3:30           Myeloid malignancy tumor board  - Panel Discussion

Kristen Pettit, MD, Michigan Medicine, Division of Hematology Oncology

Moshe Talpaz, MD, Michigan Medicine, Division of Hematology Oncology

Michael Deininger, MD, PhD, Michigan Medicine, Division of Hematology Oncology

Kamran Mirza, MBBS, PhD, Michigan Medicine, Pathology